Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System

Coronary Artery Disease Clinical Trial

— MeRes-1Extend  

Official title:

MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02663323
• Other study ID #: MER/EX
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 2, 2016
• Est. completion date: July 5, 2020

Study information

• Verified date: August 2018
• Source: Meril Life Sciences Pvt. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

MeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe, Brazil and South Africa. Primary outcome of study will be Proportion of population reporting Major Adverse Cardiac Events at 6 months from the day of index Procedure.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 64
• Est. completion date: July 5, 2020
• Est. primary completion date: October 5, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

General Inclusion Criteria:

1. Male or female subjects = 18 years of age

2. Subject is able to sign written Informed Consent Form (ICF)

3. Subjects with symptomatic myocardial ischemia, chronic stable angina

4. The patient has planned intervention of a single de novo lesion in native epicardial vessel

5. Subject who is an acceptable candidate for Coronary Artery Bypass Grafting (CABG)

6. Subject is not participating in any other clinical investigation/study and agrees not to participate in any other clinical investigation/study for a period of 3 years following the index procedure.

7. Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms and OCT as per protocol.

Angiographic Inclusion Criteria:

1. Subject with maximum two treatable de novo lesions located maximum one per native epicardial vessel located in major artery or branch, with reference vessel diameter between 2.75, 3.00 and 3.5 mm by on line QCA.

2. Target lesion length = 20 mm.

3. Subjects with Lesion(s), with a visually estimated stenosis of = 50% and < 100% with a TIMI flow of = 1.

Exclusion Criteria:

General Exclusion Criteria:

1. Subjects unable to provide written informed consent.

2. Pregnant or nursing mother and those who plan pregnancy during the clinical investigation (female patients must have a negative pregnancy test done within 7 days prior to the index procedure and effective contraceptive must be used during participation in this clinical investigation).

3. Subjects with known allergy to Poly-L-Lactide (PLLA), Poly-D,L-Lactide (PDLLA), Sirolimus (Rapamycin) or its any analog or derivative, clopidogrel, ticlopidine, prasugrel, contrast media, platinum, ticagrelor and any drug in dual antiplatelet therapy including aspirin, both heparin and bivalirudin.

4. Subject diagnosed with Acute Myocardial Infarction (AMI) within 7 days preceding the index procedure, as indicated by elevated levels of cardiac enzymes and/or ST segment changes in Electro Cardio Gram (ECG).

5. Subject with history of previous revascularization procedures including CABG and Percutaneous Coronary Intervention (PCI).

6. Subject with vascular aneurysms, cardiac arrhythmias, congestive cardiac failure having LVEF < 30%, cardiac tamponade.

7. Recipient of an organ in an organ transplant procedure or is on a waiting list for any organ transplant.

8. Subjects receiving immunosuppression therapy or having known immunosuppressive or autoimmune disease.

9. Subjects with history of stroke, Cerebro Vascular Accident (CVA) or Transient Ischemic neurological Attack (TIA). Patients with renal insufficiency where creatinine levels are more than 1.3 mg/dl, known aplastic anaemia, chronic liver disease, platelet count <100,000 cells/mm3, a WBC of < 3,000 cells/mm3.

10. Subjects planned for elective surgery within the first 12 months after the procedure that will require discontinuing dual antiplatelet therapy

11. Subject has a history of bleeding diathesis or coagulatory disease, refuses blood transfusion, significant gastrointestinal or urinary bleed within the past 12 months.

12. Subject having extensive peripheral vascular disease that precludes safe 6F sheath insertion.

13. Subject having a history of paradoxical exercise induced vasoconstriction that is consistent with myocardial bridging in the coronary anatomy.

14. Subjects participating in another clinical investigation.

15. Subjects with short life expectancy such as cancer, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or other co-morbid conditions that would limit compliance with the follow-up schedule of the study.

Angiographic Exclusion Criteria:

1. Subjects who are non-candidates for PCI.

2. Any of the target lesions meets any of the following criteria:

1. Aorto-ostial location (within 3 mm)

2. Lesion located in left main coronary artery

3. Lesion located within 2 mm of origin of the LAD or LCx

4. Lesion that involves a bifurcation with a side branch = 2mm in diameter and ostial lesion > 40% stenosed by visual estimation or side branch requiring intervention

5. Total occlusion (TIMI Flow 0), prior to wire crossing

6. Extreme tortuosity proximal to or within the lesion

7. Lesions having heavy calcification

8. Extreme angulation (= 90 %) proximal to or within the lesion

3. Evidence of previous revascularization:

1. Previous PCI with or without restenosis from previous intervention

2. Arterial or venous graft with or without lesion located within the graft or distal to a diseased arterial or saphenous vein graft

4. The target vessel contains visible thrombus.

5. Another (clinically significant or potentially significant) lesion left untreated within target vessels (including side branch) or another significant vessel.

6. Subject requiring or potentially requiring interventional procedures other than pre-dilatation and study device implantation and post dilatation.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.

Locations

Country	Name	City	State
Brazil	Instituto Dante Pazzanese de Cardiologia	Sao Paulo	SP
Indonesia	Medistra Hospital	Jakarta
Macedonia, The Former Yugoslav Republic of	University Clinic of Cardiology	Skopje
Malaysia	Institut Jantung Negara	Kuala Lumpur

Sponsors (1)

Lead Sponsor	Collaborator
Meril Life Sciences Pvt. Ltd.

Countries where clinical trial is conducted

Brazil,  Indonesia,  Macedonia, The Former Yugoslav Republic of,  Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure.		6 Month
Primary	Primary Safety Endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE) reporting at 6 months (180 days) from the day of index procedure		6 Month